FRANCIS BAYACA: Open Payments
NPI 1427067768 · WATSONVILLE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,212 in 56 payments from 19 companies in 2025. Trend: 2023 $1,326 · 2024 $1,718 · 2025 $1,212
Food & beverage: $1,212
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 12 | $226 |
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $174 |
| Novo Nordisk Inc | 6 | $147 |
| Viatris Specialty LLC | 5 | $126 |
| GlaxoSmithKline, LLC. | 4 | $84 |
| AstraZeneca Pharmaceuticals LP | 4 | $79 |
| Teva Pharmaceuticals USA, Inc. | 2 | $63 |
| PFIZER INC. | 3 | $62 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
| Amgen Inc. | 1 | $32 |
Products named: REXULTI, Kerendia, YUPELRI, Ozempic, TRELEGY ELLIPTA, AUSTEDO XR, PAXLOVID, LOKELMA.
Industry payments across CA — which companies pay providers there.
